TVGNW
Tevogen Inc.Warrants of Tevogen Inc. · TVGN stock page →
—
Market cap
$1.0M
Nano cap
1 year
−80.1%
from $31.40 · Oct 27
30 days
−7.5%
from $6.76
52-week range
$3.89–31.40
−80% from high · low Jul 20
Avg volume 20D
7.8K
Oct 23 spike 39.4K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 21 M&A: Tevogen Signs Letter of Intent to Evaluate Potential Acqui…
- E May 28 M&A: Tevogen Advances Strategic Acquisition Initiatives with Po…
- X Jul 31 Short interest jumps 4063.1% to 81.4K
- X Sep 30 Short interest jumps 80.5% to 155.7K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 0 trimmed or exited.
- TrendDOWNTREND
11% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $58.5K |
| HRT FINANCIAL LP | DOUBLED | $9.0K |
| HRT FINANCIAL LP | NEAR_EXIT | — |
| UBS Group AG | NEAR_EXIT | $18.00 |
| HRT FINANCIAL LP | TRIM | $4.0K |
| UBS Group AG | NEAR_EXIT | $97.00 |
| Parallax Volatility Advisers, L.P. | TRIM | $48.8K |
| Walleye Trading LLC | TRIM | $580.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Press release
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Both previously disclosed Nasdaq compliance matters are now closed Both previously disclosed Nasdaq compliance matters are now closed
Jul 13, 2026
Company news
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) announced that its 2026 Annual…
Jun 9, 2026
Earnings
Tevogen Announces Formation of a Healthcare Services Initiative
Tevogen launches Healthcare Services initiative to evaluate MSO and CRO acquisitions with potential to support approximately $100M in annual revenue.
May 28, 2026
M&A
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen advances strategic acquisition initiatives that, if consummated, could support financial self-sufficiency and ~$100M in annual revenue.
May 21, 2026
M&A
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen evaluates MSO acquisition as part of strategy to build revenue-generating healthcare enterprise across biotech, AI, and services.
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Other
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Both previously disclosed Nasdaq compliance matters are now closed Both previously disclosed Nasdaq
Jun 30, 2026 Inst.
SUSQUEHANNA INTERNATIONAL GROUP, LLP — DOUBLED
1,027,391 shares ($58.5K)
Jun 30, 2026 Inst.
HRT FINANCIAL LP — DOUBLED
163,909 shares ($9.0K)